FIRST PATIENT WITH BASAL CELL CARCINOMA TREATED IN NEW FOCUSED ULTRASOUND STUDY: TOOsonix A/S
Apr 19, 2022, 08:43 ET
The dermatology departments at Bispebjerg and Roskilde Hospitals, University of Copenhagen, Denmark, initiate pioneering treatment of the world's most common cancer with a new convenient, minimal-pain and easy-to-operate modality for skin oncology.
HOERSHOLM, Denmark, April 19, 2022 /PRNewswire/ -- TOOsonix A/S, a pioneer in high intensity focused ultrasound (HIFU) for dermatology, today announced that the first patients with basal cell carcinoma have been treated in a new clinical study using its System ONE-M device.
Basal Cell Carcinoma (BCC) is the most common cancer in the world. It is sun-induced, and is expected to increase in incidence along with the increase of the elderly population. Adding safe, effective and cost-efficient treatments will therefore be important for both patients and healthcare providers around the world.
The clinical study will include 40 patients diagnosed with superficial BCC. The HIFU treatment will be administered as a single dosing of approximately 1-2 minutes of active focused ultrasound. The treatment does not require any local anesthetics and no special after-care. Study participants are monitored with regular follow-up visits over 12 months after treatment. An interim report with evaluation of cure rate and safety profile 3 months after treatment is planned.
The TOOsonix high intensity focused ultrasound system used in the study delivers highly accurate doses of energy to focal points in a chosen depth. It can therefore directly and selectively treat areas affected by basal cell carcinoma, typically invading the outer layer of the human skin.
"After initial medical CE-marking of the system in June 2020, treatment data coming from selected hospitals and private clinics have been very positive, demonstrating that the system is very versatile, and can be used to treat a large range of different dermatological conditions. We have continued to support leading university hospitals with the devices and information necessary to start larger formalized clinical studies. We are therefore now very proud to see this first study on a broad range of patients suffering from the most common cancer in the world", state Torsten Bove and Tomasz Zawada, founders of TOOsonix.
Professor, M.D, Joergen Serup, who lead the study at Bispebjerg Hospital, comment: "High frequency HIFU has a significant potential for future use in treatment of BCC and other dermatological conditions. In experimental work, it has already been indicated that the device has important practical and resource-saving advantages over photodynamic therapy (PDT), which is a leading therapy in superficial and early-stage BCC. Noteworthy is the reduced pain-level during treatment. HIFU can be applied to multiple sites of the body in one short session, and therefore has the potential to replace cumbersome and resource-demanding PDT in the future. Recurrent BCC after any previous treatment is a logic indication, taking advantage of the focused and targeted principle of the method. The method is for the same reason expected to carry low risk of post-treatment scarring and dyschromia. The method can work well in hospitals as well as private practice settings".
About TOOsonix System ONE-M
System ONE-M is a focused ultrasound device operating at 20 MHz, which creates thermal focal zones in the epidermis and dermis of the human skin. Within the focal zone, the temperature rapidly increases to 50–60 °C, which causes local cell death. The body's own healing processes will subsequently remove and replace the treated field with new and healthy tissue. The system provides an innovative and easy-to-use image-guided treatment modality, that enables physicians and other qualified practitioners to offer convenient, safe and effective therapy to their patients. The device has in published case-series been demonstrated to provide positive outcome in various dermatological conditions, such as actinic keratosis, basal cell carcinoma and Kaposi sarcoma. The new clinical data and documentation from on-going studies will be used to expand the list of indicated use in the near future.
About TOOsonix A/S
TOOsonix is a Danish company pioneering therapeutic ultrasound for dermatological indications with its unique and patented high-frequency focused ultrasound device. The company was founded in 2017 on the foundations of more than 35 years' experience in ultrasonic technology and devices. The company has financial backing from one of Denmark's most successful private investor companies.
TOOsonix A/S, Agern Alle 1, DK 2970 Hoersholm, Denmark
Ph: +45 2059 2999
Email: [email protected]
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Press release (PDF)
TOOsonix HIFU Treatment - BCC
TOOsonix HIFU Treatment
TOOsonix system ONE-M
SOURCE TOOsonix A/S
Share this article